Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. (Japan) holds 1 active US FDA Type II Drug Master File and 12 inactive, has DMF or CEP filings on record for 6 active ingredients and is linked to 3 FDA-registered manufacturing sites. 39 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Otsuka Pharmaceutical Co., Ltd.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/otsuka-pharmaceutical-co-ltd
Overview
Otsuka Pharmaceutical Co., Ltd. is a Japanese multinational pharmaceutical company specializing in the development and commercialization of innovative drugs. The company is known for its research in areas such as immunology, nephrology, and oncology.
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which Otsuka Pharmaceutical Co., Ltd. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Otsuka Pharmaceutical Co., Ltd. holds 1 active (13 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- OPA-15406 DRUG SUBSTANCEActive2016-05-23
- REBAMIPIDE(OPC-12759) DRUG SUBSTANCEInactive2000-08-10
- NO-1886 DRUG SUBSTANCEInactive1998-10-15
- NADIFLOXACIN DRUG SUBSTANCEInactive1997-03-01
- FORMULATION RESEARCH INSTITUTE IN TOKUSHIMA, JAPANInactive1993-05-20
- COMMERCIAL BULK PLANT OF SECOND TOKUSHIMA FACTORY IN TOKUSHIMA, JAPANInactive1992-10-05
- FACILITIES AND OPERATING PROCEDURES AT THE SAGA FACTORY, JAPANInactive1992-08-21
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN TOKUSHIMA, JAPAN.Inactive1992-01-10
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN TOKUSHIMA, JAPAN.Inactive1985-11-07
- MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN TOKUSHIMA, JAPAN.Inactive1985-11-07
- PROCATEROL, AEROSOL FORMULATION PRODUCED IN TOKUSHIMA FACTORYInactive1983-01-17
- PROCATEROL HYDROCHLORIDE HEMIHYDRATEInactive1979-09-19
- CARTEOLOL HCLInactive1976-05-13
Registered manufacturing sites (3)
Physical sites registered with the US FDA and resolved to Otsuka Pharmaceutical Co., Ltd., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
FDA compliance signals
39 FDA enforcement records linked to this company.
- 4832025-06-17
Scientifically sound laboratory controls
- 4832025-06-17
Environmental Monitoring System
- 4832025-06-17
Validation lacking for sterile drug products
- 4832025-06-17
Absence of Written Procedures
- 4832019-10-22
Procedures not in writing, fully followed
- 4832019-10-22
Cleaning / Sanitizing / Maintenance
- 4832019-10-22
Written procedures followed
- 4832019-10-22
Computer control of master formula records
- 4832019-10-22
Investigations of discrepancies, failures
- 4832019-10-22
Written record of complaint to include findings, follow-up
- 4832019-10-22
Annual visual exams of drug products
- 4832019-02-15
Following/documenting laboratory controls
- 4832019-02-15
Written procedures not established/followed
- 4832019-02-15
Cleaning / Sanitizing / Maintenance
- 4832019-02-15
Control procedures to monitor and validate performance
- 4832016-09-22
Failure to review ADE information
- 4832016-07-22
Representative Samples
- 4832016-07-22
Strict control not exercised over labeling issued
- 4832016-07-22
Packaging line inspection before use
- 4832016-07-22
Procedures not in writing, fully followed
- 4832016-07-22
Complete Test Data
- 4832016-07-22
Returned drug procedures in writing and followed
- 4832016-07-22
Cleaning / Sanitizing / Maintenance
- 4832014-06-17
Investigations of discrepancies, failures
- 4832014-06-17
Procedures for sterile drug products
- 4832014-06-17
Annual visual exams of drug products
- 4832014-03-20
Establishment of calibration procedures
- 4832014-03-20
Written record of investigation incomplete
- 4832014-03-20
Written procedures not established/followed
- 4832014-03-20
Rotation of components/containers/closures
- 4832012-08-02
Written procedures fail to include
- 4832012-08-02
Procedures not in writing, fully followed
- 4832012-08-02
Procedures for non-sterile drug products
- 4832011-10-21
Calibration - at intervals, written program, remedial action
- 4832011-10-21
Absence of Written Procedures
- 4832011-10-21
Control procedures fail to include the following
- 4832011-10-21
Annual visual exams of drug products
- 4832011-10-21
Valid stability test methods
- 4832011-10-21
Complete test data included in records
Is this Otsuka Pharmaceutical Co., Ltd.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.